Squamous cell carcinoma of the skin future or investigational therapies
|
Squamous cell carcinoma of the skin Microchapters |
|
Differentiating Squamous cell carcinoma of the skin from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Squamous cell carcinoma of the skin future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Squamous cell carcinoma of the skin future or investigational therapies |
|
FDA on Squamous cell carcinoma of the skin future or investigational therapies |
|
CDC on Squamous cell carcinoma of the skin future or investigational therapies |
|
Squamous cell carcinoma of the skin future or investigational therapies in the news |
|
Blogs on Squamous cell carcinoma of the skin future or investigational therapies |
|
Directions to Hospitals Treating Squamous cell carcinoma of the skin |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2], Raviteja Guddeti, M.B.B.S. [3]
Future or Investigational Therapies
In 2007, Australian biopharmaceutical company Clinuvel Pharmaceuticals Limited began clinical trials with a melanocyte-stimulating hormone called melanotan (known by the International Nonproprietary Name afamelanotide, formerly CUV1647)[1] to provide photoprotection for organ transplant patients against squamous cell carcinoma of the skin and actinic keratosis.[2][3]
Cetuximab a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), has antitumor activity in patients with advanced squamous cell carcinoma of the skin, as initially suggested by case reports.
Use of natural agents in cancer therapy is increasing. For oral squamous cell carcinoma , use of curcumin microemulsions is under considerations. New modalities like use of ultra sound mediated delivery of these microemulsions. [4]
References
- ↑ "World Health Organisation assigns CUV1647 generic name" (PDF). Clinuvel. 2008. Retrieved 2008-06-17.
- ↑ Clinuvel » Investors » FAQs
- ↑ PharmaAsia - Clinuvel’s Drug Begins Global Phase II Skin Cancer Trials
- ↑ Lenaz G, Fato R, Baracca A, Solaini G, Parenti Castelli G, Rabbi A (1988). "Dynamics of biological membranes". Ann. Ist. Super. Sanita. 24 (1): 9–21. PMID 3289448.